Palosuran
| Title | Journal |
|---|---|
| Prolidase could act as a diagnosis and treatment mediator in lung fibrosis. | Inflammation 20121001 |
| The efficiency of a urotensin II antagonist in an experimental lung fibrosis model. | Inflammation 20120601 |
| Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. | The Journal of clinical endocrinology and metabolism 20120601 |
| Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. | PloS one 20120101 |
| Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. | PloS one 20120101 |
| Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist. | Assay and drug development technologies 20111001 |
| Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance. | PloS one 20110101 |
| Link-based quantitative methods to identify differentially coexpressed genes and gene pairs. | BMC bioinformatics 20110101 |
| Potential Clinical Implications of the Urotensin II Receptor Antagonists. | Frontiers in pharmacology 20110101 |
| Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals. | Neuroscience 20100929 |
| Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. | ChemMedChem 20100903 |
| Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. | Digestive diseases and sciences 20100501 |
| Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. | Hypertension (Dallas, Tex. : 1979) 20100501 |
| Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. | Pediatric research 20100201 |
| Late-onset circulatory dysfunction after thyroid hormone treatment in an extremely low birth weight infant. | Journal of pediatric endocrinology & metabolism : JPEM 20100101 |
| Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. | Journal of medicinal chemistry 20091210 |
| Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. | Regulatory peptides 20091009 |
| Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. | Journal of clinical pharmacology 20091001 |
| Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. | British journal of clinical pharmacology 20091001 |
| Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. | The Journal of clinical endocrinology and metabolism 20090201 |
| Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. | British journal of pharmacology 20081001 |
| Urotensin II in cardiovascular regulation. | Vascular health and risk management 20080801 |
| Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. | Peptides 20080501 |
| Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas. | Peptides 20080501 |
| Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. | Peptides 20080501 |
| Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. | Peptides 20080501 |
| Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. | Hepatology (Baltimore, Md.) 20080401 |
| Non peptidic urotensin II antagonists: perspectives for a new class of drugs. | Cardiovascular & hematological agents in medicinal chemistry 20080401 |
| Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. | Cardiology in review 20080101 |
| Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus. | International journal of biological sciences 20080101 |
| Role of urotensin II and its receptor in health and disease. | Journal of anesthesia 20070101 |
| Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. | International journal of molecular medicine 20061201 |
| Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. | Clinical pharmacology and therapeutics 20060901 |
| Urotensin-II and UII-receptor expression and function in the rat adrenal cortex. | International journal of molecular medicine 20060601 |
| The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. | The Journal of pharmacology and experimental therapeutics 20060301 |
| Effect of lesions of cerebellar fastigial nuclei on lymphocyte functions of rats. | Neuroscience research 20050301 |
| Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. | The Journal of pharmacology and experimental therapeutics 20041001 |